TGFβ/SMAD3 signaling can significantly impact the outcome of CDK inhibitor therapy, both through canonical signaling as a cell-cycle inhibitory pathway, as well as through immunosuppressive effects in the cancer microenvironment. The gene discussed is TGFB1; the disease is cancer.